Mobile

A randomized, double-blind, placebo controlled, cross-over, multi-center study to assess the effect of the GLP-1 analogue LY307161 in patients suffering from Irritable Bowel Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004264-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To test the hypothesis that LY307161, will reduce the acute abdominal pain attacks in patients suffering from irritable bowel syndrome (IBS). The primary endpoint will be the proportion of responders after each treatment, as estimated from pain relief ratings.

Critère d'inclusion

  • Irritable Bowel Disease

Liens